Photo by kellysikkema from unsplash
Recent changes in the market for left ventricular assist devices have resulted in the HeartMate 3 (HM3) being the only commercially‐available device. This study evaluates the outcomes of patients with… Click to show full abstract
Recent changes in the market for left ventricular assist devices have resulted in the HeartMate 3 (HM3) being the only commercially‐available device. This study evaluates the outcomes of patients with a HM3 waitlisted for and undergoing orthotopic heart transplantation (OHT).
Keywords:
ventricular assist;
heartmate left;
device strategy;
assist device;
left ventricular
Journal Title: Journal of Cardiac Surgery
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of Cardiac Surgery
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!